Who are Sandimmune's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Elidel, Prograf, CYCLOSPORINE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ciclosporin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Sandimmune — Competitive Intelligence Brief

Sandimmune (Ciclosporin) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcineurin Inhibitor Immunosuppressant [EPC]. Area: Oncology.

marketed Calcineurin Inhibitor Immunosuppressant [EPC] Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Sandimmune (Ciclosporin) — Novartis.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sandimmune TARGET	Ciclosporin	Novartis	marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	1983-01-01
Elidel	PIMECROLIMUS	Bausch Health	marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	Peptidyl-prolyl cis-trans isomerase FKBP1A	2001-01-01
Prograf	TACROLIMUS	Astellas Pharma	marketed	Calcineurin Inhibitor Immunosuppressant	Interferon gamma	1994-01-01
CYCLOSPORINE	CYCLOSPORINE		marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	calcineurin	1983-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-11-03 — Sandimmune · 8298568 · US
2028-05-30 — Prograf · 11123331 · Method of Use · US
2028-05-30 — Prograf · 12403095 · Formulation · US
2028-05-30 — Prograf · 9549918 · Formulation · US
2028-05-30 — Prograf · 11419823 · Formulation · US
2028-05-30 — Prograf · 10166190 · Formulation · US
2028-05-30 — Prograf · 10864199 · Method of Use · US
2028-05-30 — Prograf · 11110081 · Method of Use · US
2028-05-30 — Prograf · 12083103 · Method of Use · US
2028-08-30 — Prograf · 8685998 · Formulation · US
2028-08-30 — Prograf · 8664239 · Method of Use · US
2029-06-02 — Sandimmune · 9132071 · US
2030-12-13 — Sandimmune · 8614178 · US
2031-02-25 — Sandimmune · 8292129 · US
2032-04-16 — Sandimmune · 8561859 · US
2033-08-23 — Sandimmune · 10441630 · US
2033-08-23 — Sandimmune · 9937225 · US
2033-08-23 — Sandimmune · 8980839 · US
2034-02-07 — Sandimmune · 9676525 · US
2034-05-11 — Sandimmune · 9669974 · US
2037-02-28 — Sandimmune · 10918694 · US
2037-09-22 — Sandimmune · 10813976 · US
2038-11-20 — Sandimmune · 11154513 · US
2039-10-11 — Sandimmune · 11413323 · US

Sponsor landscape (Calcineurin Inhibitor Immunosuppressant [EPC] class)

· 1 drug in this class
Bausch Health · 1 drug in this class
Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sandimmune — Competitive Intelligence Brief. https://druglandscape.com/ci/ciclosporin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab